Kiev Mayor's $6M Villa: Vitaly Klitschko
The Big Business of Longevity
Eight molecules carry an FDA label. Six carry a nonbinding committee vote. The gray market sells the second as though it were the first. A field report on the longevity pipeline, the capital behind it, and the listed names that matter.
AI Intelligence Scales. Accountability Does Not. Why KXCO Is Built for It.
Capability is becoming abundant and everything abundant gets cheap. What does not get cheap is the person who has to sign, and they can only carry what they can see. Four conditions follow from that, and four independent authorities reached the first of them last month without knowing it.
KXCO Quantum Toolkit: The Cryptography You Did Not Choose Is Already in Your Software
Almost no company can say what cryptography actually runs inside its own software, and auditors have started asking. KXCO publishes five free packages that find it, replace it with the NIST post-quantum standards, and fail the build when someone gets it wrong.
The Hottest Biotechs of 2026
Twenty FDA approval actions so far in 2026, eight of them inside a sixteen-day window in August. A first-in-class RAS inhibitor that doubled survival in pancreatic cancer, an oral GLP-1 cleared in fifty days, a first gene therapy for GSDIa, and seven AI platforms with nine assets in humans and nothing yet approved.
Every story, signed and delivered.
Subscribe to the kxco channel and get the headline, the AI-written key takeaways, and the chain-anchor link the moment we publish. Audio versions and per-ticker subscriptions arrive in the next iteration.